Fewer than one in 10 individuals who could benefit from obesity jabs like Wegovy are able to get them, caution the WHO as it issues its initial advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is calling for increased and just availability to this class of drugs.
Per projections, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"Our latest guidelines recognises that obesity is a lifelong illness that can be treated with thorough and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are key hurdles to widespread availability to the jabs that can aid individuals in losing considerable body mass, explains the organization.
GLP-1 Therapy Scarcity
Despite the present best projected case, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The advice urges nations and manufacturers to widen access, by measures such as patent sharing.
The intellectual property rights on a key compound – the core component of a leading brand – is due to expire in several countries in 2026.
The Way Obesity Jabs Work
The injections replicate a body's own hormone to delay gastric emptying, curb appetite and increase satiety so individuals consume fewer calories.
Individuals usually see weight reduction within a few weeks of starting on the once-weekly jabs.
Studies points to users may see weight return after a year of halting the drug, when their usual appetite come back.
Being carrying excess weight increases your likelihood for experiencing diseases, including type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight impacts people in every country and was linked to millions of fatalities worldwide in 2024, as per the health agency.
